Biopharma’s next competitive edge won’t come from the lab—it’ll come from the tender desk.
If you’re a commercial vendor selling tender strategy consulting into EU markets, the window is narrowing—and the winners will be the ones who treat tendering …

Pharma doesn’t always need a new molecule to make billions.
Sometimes it just needs a new story—and the legal scaffolding to protect it.
That’s the core idea behind “new drug, old molecule”: the strategy where companies take an existing active ingred…

Biopharma is entering a new kind of cliff—not the one on the label, but the one in the contract.
As patents approach loss of exclusivity, the market doesn’t just get more competitive. It gets more operationally unforgiving. Generic and authorized gener…

One-shot: How to pick the right drug patent for maximum extension value
Most pharma teams don’t lose patent value because they miss the science. They lose it because they pick the wrong legal lever—too late, too narrowly, or with the wrong assumptions …

Drug patent “design-around” isn’t a buzzword—it’s a discipline.
In pharma, the fastest way to get stuck isn’t a bad molecule. It’s a bad patent strategy.
A recent piece from DrugPatentWatch on the art of design-around gets to the heart of why: infrin…

Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …

Pharma has a $300 billion question it can’t afford to misread: Is it “patent term restoration” or “patent term adjustment”?
On paper, the two concepts sound like close cousins. In practice, they can mean the difference between a blockbuster’s launch …

Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…

Pharma executives don’t lose in Eurasia because they didn’t know the science. They lose because they didn’t know the rules of time.
That’s the real takeaway from Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know—and it’s a war…

Pharmaceutical patent strategy is often discussed like a binary choice: fight for every right, or give up and move on. But the real world is messier—and more expensive.
In a recent piece from DrugPatentWatch, the “cut, keep, or cash” framework reframes…